Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 12065445 CDK2 inhibitors and methods of using the same

Patent 12065445 was granted and assigned to Cedilla Therapeutics on August, 2024 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Patent Applicant

Cedilla Therapeutics

0

Current Assignee

Cedilla Therapeutics

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Wojtek Michowski0

Carl Eric Schwartz0

Louise Clare Kirman0

Justin Ripper0

Dale A. Porter, Jr.0

John Paul Sherrill0

Thomas P. Blaisdell0

John Feutrill0

Date of Patent

August 20, 2024

0

Patent Application Number

176492690

Date Filed

January 28, 2022

0

Patent Citations

US Patent 7592373 Amide compounds with MCH antagonistic activity and medicaments comprising these compounds

0

US Patent 7638526 Azetidine derivatives useful in treating pain, diabetes and disorders of lipid metabolism

0

US Patent 7834026 Spirocyclic compounds

0

US Patent 8232288 Substituted benzimidazoles, benzothiazoles and benzoxazoles

0

US Patent 8349825 Spirocyclic compounds

0

US Patent 7351719 Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds

0

US Patent 7435830 Bicyclic and bridged nitrogen heterocycles

0

US Patent 7435831 Bicyclic and bridged nitrogen heterocycles

0

...

Patent Primary Examiner

Jeffrey H Murray

0

CPC Code

0

0

0

0

0

0

0

0

...

No article content yet.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 12065445 CDK2 inhibitors and methods of using the same

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.